Clinical Trials for Colon Cancer

Ablative Dose Single Fraction MRguided Colorectal Liver Metastasis SBRT

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: This trial enrolls adults with 1-3 measurable colorectal cancer liver metastases (with specific size/location criteria), ECOG 0-2, and no cirrhosis, including those with prior therapies or extrahepatic disease, to receive a single 40 Gy fraction of MR-guided, adaptive SBRT for local control.

ClinicalTrials.gov ID: NCT06130280

Pilot Study Evaluating Microbiome Modulation Therapy (MBMT) With Ciprofloxacin, Metronidazole, and Aspirin in Addition to Standard of Care Chemotherapy in Patients Undergoing First-Line Therapy for Metastatic Colorectal Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with newly diagnosed metastatic (stage IV) colorectal cancer eligible for first-line 5-fluorouracil-based doublet chemotherapy are randomized to standard chemotherapy with or without an investigational microbiome modulation therapy (MBMT) consisting of oral ciprofloxacin, metronidazole, and low-dose aspirin, aiming to assess whether altering the gut microbiome improves treatment response. Patients with recent antibiotic use, high bleeding risk, or MBMT drug allergies are excluded.

ClinicalTrials.gov ID: NCT06728072

A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Recurrent, Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: This trial enrolls adults with recurrent, unresectable, or metastatic KRAS/NRAS/BRAF wild-type colorectal cancer who have progressed after prior fluoropyrimidine- and oxaliplatin-based chemotherapy, randomizing them to receive either amivantamab (a bispecific EGFR/MET antibody) plus FOLFIRI or standard of care FOLFIRI with either cetuximab or bevacizumab. Prior irinotecan, EGFR, MET, or HER2-targeted therapies are exclusionary.

ClinicalTrials.gov ID: NCT06750094

Sequential Combined TAS-102 and Oxaliplatin Alternating With TAS-102 and Irinotecan (Sequential TASOXIRI) With Bevacizumab for Late-Line Metastatic Colorectal Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: This trial enrolls adults with metastatic colorectal cancer who have progressed after standard chemotherapies (including 5-FU, oxaliplatin, irinotecan, and appropriate antibody therapies), evaluating a sequential regimen of TAS-102 (nucleoside metabolic inhibitor) alternating with oxaliplatin and irinotecan plus bevacizumab. Patients must not have had prior TAS-102 exposure and should have good performance status and organ function.

ClinicalTrials.gov ID: NCT05806931

Randomized Phase II Trial of 5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with metastatic colorectal cancer who have failed at least two prior lines of therapy and meet standard eligibility criteria are randomized to receive either 5-fluorouracil/leucovorin with regorafenib (an oral multikinase inhibitor targeting angiogenic, stromal, and oncogenic pathways) or trifluridine-tipiracil plus bevacizumab.

ClinicalTrials.gov ID: NCT06887218

A Phase 1/2 Study of Tegavivint (NSC#826393) in Children, Adolescents, and Young Adults With Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial enrolls children, adolescents, and young adults with recurrent or refractory solid tumors (including lymphomas and desmoid tumors), treating them with intravenous tegavivint, a small molecule inhibitor targeting TBL1 to disrupt Wnt/beta-catenin signaling. Expansion cohorts focus on specific tumor types and Wnt pathway–driven malignancies.

ClinicalTrials.gov ID: NCT04851119

A Phase I/Ib Global, Multicenter, Open-label Umbrella Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with previously treated metastatic colorectal adenocarcinoma whose tumors harbor specific biomarkers are assigned to various arms testing targeted agents—including the PI3Kα inhibitor inavolisib, TIGIT inhibitor tiragolumab (with anti–PD-L1 and bevacizumab), CDK7 inhibitor SY-5609, and KRAS G12C inhibitor divarasib (with chemotherapy or EGFR/VEGF antibodies)—according to their molecular profile.

ClinicalTrials.gov ID: NCT04929223

A Randomized Trial of Microbiotic Product (NBT-NM108) to Promote Microbiome Health and Improve Chemotherapy Delivery

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

TrialFetch AI summary: This trial enrolls adults with metastatic colon cancer who are candidates for second-line or later irinotecan-based chemotherapy, randomizing them to receive standard chemotherapy with or without NBT-NM108, an oral botanical agent designed to modulate the gut microbiome and boost short-chain fatty acid production. Patients must have good performance status and no significant baseline diarrhea; the study aims to assess whether NBT-NM108 reduces diarrhea and enables improved chemotherapy delivery.

ClinicalTrials.gov ID: NCT05296681

A Single Arm Phase 4 Trial to Evaluate the Safety and Efficacy of Oral Fruquintinib in the Treatment of Refractory Metastatic Colorectal Cancer in Patients From Minority Populations Underrepresented in Prior Fruquintinib Studies

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: This trial enrolls adult patients with refractory metastatic colorectal adenocarcinoma who self-identify as Black/African American or Hispanic/Latino and have ECOG 0–1, treating them with oral fruquintinib, a VEGFR 1/2/3 inhibitor, to assess safety—particularly incidence of hypertension—and efficacy in this underrepresented population.

ClinicalTrials.gov ID: NCT06562543

Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb for Treatment-naïve Subjects With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (CodeBreaK 301)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: This trial enrolls treatment-naïve adults with metastatic colorectal adenocarcinoma harboring a KRAS p.G12C mutation and randomizes them to receive either sotorasib (a KRAS G12C inhibitor), panitumumab, and FOLFIRI, or FOLFIRI with or without bevacizumab-awwb. Excludes include prior KRAS G12C inhibitor use, untreated CNS metastases, and significant pulmonary disease.

ClinicalTrials.gov ID: NCT06252649